China's coronavirus vaccine shows military's growing role in medical research.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.Biomedicines · 2022
   Review
2. Declining rates of global routine vaccination coverage amidst the COVID-19 syndemic: a serious public health concern.Einstein (Sao Paulo, Brazil) · 2022
   Article
3. The Immunopathobiology of SARS-CoV-2 Infection.FEMS microbiology reviews · 2021
   Article
4. A Review on Current COVID-19 Vaccines and Evaluation of Particulate Vaccine Delivery Systems.Vaccines · 2021
   Review
5. Emergency use authorisation for COVID-19 vaccines: lessons from Ebola.Lancet (London, England) · 2020
   Article

Corrections and comments

• Comment on
  Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as